Merck KGaA to buy Springworks for $3.9 billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Source: SeekingAlpha
Merck KGaA Acquisition: Merck KGaA is set to acquire U.S. biotech company SpringWorks Therapeutics for $3.9 billion, with the purchase price at $47 per share, aimed at enhancing its cancer drug portfolio and expanding its presence in the U.S. market.
Strategic Growth Focus: The acquisition is expected to boost immediate revenue and support long-term growth, as Merck KGaA continues to seek further M&A opportunities that align with its strategic goals and financial stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
